|
PROVENGE Now Broadly Available
|
PROVENGE Now Broadly Available
iReport — Dendreon Corporation (Nasdaq: DNDN) announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC). To view Multimedia News Release, go to
Video Length: 0
Date Found: July 06, 2011
Date Produced:
View Count: 0
|
|
|
|
|
I got punched by an old guy, for farting near his wife. Read MoreComic book creator Stan Lee talks the future of the medium in the digital age. Panelists Zachary... Read MoreThe U.S. launch of Spotify is still on music lovers' minds. Join Zachary Levi, from NBC’s... Read MoreTuesday: Rupert Murdoch testifies before Parliament on the hacking scandal that brought down "News... Read MoreAfter a long slump, the home construction industry may be showing signs of life. But as Bill... Read More | 1 2 3 4 5 |
|
|
|